In 2017 the University of Sheffield was commissioned by Public Health England (PHE) to develop a new return on investment (ROI) tool for cardiovascular disease (CVD) prevention, to be used by national and local decision-makers. The tool focuses on prevention of CVD in six key high-risk groups, identified through the NHS RightCare pathway as being currently underdiagnosed and insufficiently well managed. This includes patients with hypertension, diabetes (type 1 and type 2), non-diabetic hyperglycaemia, atrial fibrillation, chronic kidney disease and high cholesterol (the latter including patients with a QRISK2 score ≥ 10% or familial hypercholesterolaemia).
Cardiovascular disease (CVD) prevention has been highlighted by the Next Steps on the Five Year Forward View as a key priority for clinical commissioning groups (CCGs). An important area of focus is improving the management of high-risk conditions for CVD, such as atrial fibrillation (AF). In response to this escalating healthcare priority, Imperial College Health Partners have developed the new AF High Impact Intervention Tool in collaboration with NHS RightCare, as part of their CVD Prevention Pathway.
We know that there are differences in outcomes between populations that cannot be explained by the dictates of evidence-based medicine or by demographics. Core to the work of NHS RightCare is the concept of unwarranted variation and the vital importance of using our shared NHS resources to deliver the best outcomes for our population. In 2018, NHS RightCare developed the toolkit for physical ill health and cardiovascular disease (CVD) prevention in people with severe mental illness (SMI), in close collaboration with Public Health England (PHE).
Familial hypercholesterolaemia (FH) is a common monogenetic condition that causes high levels of cholesterol in the blood, resulting in an increased risk of heart disease at an early age. FH affects around one in every 270 people. That means that in England around 160,000 adults and 40,000 children under 18 years are likely to have FH, though only around 3,000 have been diagnosed by DNA testing. This article discusses the new implementation guide, which is designed to improve the identification and treatment of people with FH.
Community pharmacists are widely recognised as an under-utilised resource within the NHS, in spite of their skills and experience, and the accessibility of their premises. In recent years, community pharmacists have demonstrated the value of the clinical services they offer, particularly in the prevention of cardiovascular disease (CVD).
Foot ulceration in people with diabetes is an increasing problem which is costly to the NHS financially and to patients in terms of quality of life. Management is complex and involves a team approach to ensure the best results for patients.
As many as 16 million people in the UK are estimated to have hypertension, and around 7 million of these are undiagnosed. Of those diagnosed in England, one third are not receiving optimum management.
Cardiovascular disease (CVD) is the leading cause of death worldwide. Elevated blood pressure (BP) is the main global risk factor for premature morbidity and mortality, and the prevalence of hypertensive heart disease is not declining over time. Improved control of high BP is, therefore, fundamental to further prevention of CVD, and adoption of treatment guidelines can have a positive impact on BP-related outcomes.
Given that cardiovascular disease (CVD) is responsible for a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas, the NHS Long Term Plan recognises that CVD is the single biggest area where the NHS can save lives over the next 10 years.
In the 70 years since the NHS was founded there have indeed been remarkable successes in reducing mortality from common conditions, an important example being deaths due to heart and circulatory disease. Yet the statistics show that there is more to be done to prevent the toll of premature death and years of disability associated with CVD. For this reason, we welcome the continuing focus on CVD prevention as set out in this publication, produced with the support of PHE and NHS England.
Over the last few decades, there has been a great focus on reducing premature deaths due to cardiovascular disease (CVD). Although this is true, CVD still remains a significant cause of disability and death in the United Kingdom. With nearly 7 million people are living with CVD in England, and a quarter of deaths each […]